康希诺生物（06185.HK）今日盘中大涨5.01%，引发投资者关注。该公司最新发布的第三季度财报显示，业绩大幅改善，尤其是盈利能力的显著提升。
根据公司公告，康希诺生物第三季度实现营业收入3.10亿元，同比增长17.67%；归属于上市公司股东的净利润2792.56万元，同比大幅增长842.01%。前三季度累计实现营业收入6.93亿元，同比增长22.13%；归属于上市公司股东的净利润1444.01万元，实现扭亏为盈。
康希诺生物表示，第三季度业绩的强劲增长主要源于核心产品曼海欣的出色市场表现。作为中国流脑疫苗领域唯一的四价流脑结合疫苗产品，曼海欣凭借其创新优势，展现出强劲的市场竞争力，市场占有率不断攀升。这一核心产品的放量增长，推动了公司整体业绩的显著提升，为股价上涨提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.